Key result
Adjuvant doxorubicin and cyclophosphamide for breast cancer is linked to ~40% incidence of moderate-to-severe anemia.
Why the study?
The incidence and severity of prechemotherapy anemia and chemotherapy-induced anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide were not well described.
Observational (n=310)
Yes
A significant proportion of stage II and III breast cancer patients are anemic prior to chemotherapy, and the incidence of moderate to severe anemia increases substantially during doxorubicin and cyclophosphamide treatment.
Answers are grounded in this paper and cite their sources.
Anemia common and often untreated in early breast cancer on AC chemo; leaves open whether proactive monitoring or intervention improves outcomes.
Learning Objectives After completing this course, the reader will be able to: Identify the prevalence and incidence of anemia in early-stage breast cancer patients and the proportion of patients untreated for anemia. Discuss the relationship between certain patient characteristics (i.e., age and prechemotherapy hemoglobin level) and the risk of developing moderate to severe anemia during chemotherapy. Explain how anemia may progress from cycle to cycle of chemotherapy and quantify the drop in hemoglobin levels for different groups of patients. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Purpose. The incidence and severity of prechemotherapy anemia and chemotherapy-induced anemia experienced by women treated with adjuvant doxorubicin and cyclophosphamide (AC) therapy for stage II and III breast cancer are described. Patients and Methods. Medical charts of 310 breast cancer patients who received chemotherapy at eight oncology practices during 1997 through 2001 were reviewed in this historical case series study. Prechemotherapy anemia was defined as a baseline hemoglobin value <12 g/dl. An anemic event during chemotherapy (used to define chemotherapy-induced anemia) was defined as either a drop in hemoglobin level below the threshold (≤10 g/dl), the receipt of a blood transfusion(s), or treatment with epoetin alfa. Results. Overall, 40.0% of patients experienced moderate to severe anemia (i.e., their hemoglobin levels dropped to <10 g/dl) and 31.3% (97/310) were anemic prechemotherapy. Of the patients with mild anemia prechemotherapy, 61.9% developed moderate to severe anemia during chemotherapy. Only 47.4% (46/97) of those patients received epoetin alfa therapy during chemotherapy. Of the patients with normal prechemotherapy hemoglobin levels (≥12 g/dl), 88.3% developed some degree of anemia (<12 g/dl) during chemotherapy and 27.7% (59/213) developed moderate to severe anemia (<10 g/dl). Anemic events were experienced by 41.8% (89/213) of the patients with normal prechemotherapy hemoglobin levels. Conclusions. We conclude that a significant proportion (31.3%) of stage II and III breast cancer patients are anemic prechemotherapy and that the incidence of anemia increases substantially from prechemotherapy through the postchemotherapy period. This evidence appears to warrant earlier evaluation of anemia and an intervention in the prechemotherapy stage.
No takes yet. Share an insight, caveat, or question.
Kirshner et al. (2004) conducted an observational in Stage II and III Breast Cancer (n=310). Adjuvant doxorubicin and cyclophosphamide (AC) chemotherapy was evaluated on Moderate to severe anemia (hemoglobin <10 g/dl) during chemotherapy. In women with stage II and III breast cancer receiving adjuvant doxorubicin and cyclophosphamide, 31.3% were anemic prechemotherapy and 40.0% developed moderate to severe anemia during treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: